Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analysts remain bullish on Teva: Eleven of 12 analysts rate the stock a “buy,” producing a consensus “Moderate Buy” rating and an average 12-month price target of $43.73. Recent targets range from $42 to $50.
• Insiders sold shares while institutions increased holdings: Insiders sold nearly 375,000 shares worth approximately $14.6 million over the past 90 days, while institutional investors and hedge funds own 54.05% of the stock.
• TEVA shares opened at $39.84, near their 52-week high of $40.79, with a market capitalization of $46.43 billion. The company reported quarterly revenue of $4.14 billion and analysts expect full-year earnings of $1.95 per share.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $43.73.

TEVA has been the topic of several recent analyst reports. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a "buy" rating in a report on Friday, September 4th. Barclays raised their price target on shares of Teva Pharmaceutical Industries from $40.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. Leerink Partners started coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 price target on the stock. Oppenheimer assumed coverage on Teva Pharmaceutical Industries in a report on Wednesday, September 23rd. They issued an "outperform" rating and a $50.00 price objective on the stock. Finally, Piper Sandler increased their price objective on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 28th.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 367,600 shares of the company's stock in a transaction on Friday, September 18th. The stock was sold at an average price of $39.06, for a total value of $14,358,456.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Brian Savage sold 7,342 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total value of $285,236.70. Following the transaction, the insider owned 8,500 shares of the company's stock, valued at approximately $330,225. This represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 374,959 shares of company stock worth $14,644,285. Corporate insiders own 0.54% of the company's stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the stock. QRG Capital Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 17.0% in the 2nd quarter. QRG Capital Management Inc. now owns 89,078 shares of the company's stock valued at $3,018,000 after acquiring an additional 12,925 shares during the period. Envestnet Portfolio Solutions Inc. boosted its position in shares of Teva Pharmaceutical Industries by 7.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,311 shares of the company's stock worth $248,000 after purchasing an additional 483 shares during the period. Bullseye Investment Management LLC acquired a new stake in Teva Pharmaceutical Industries in the 2nd quarter valued at approximately $68,000. Sequoia Financial Advisors LLC increased its holdings in Teva Pharmaceutical Industries by 12.5% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 190,940 shares of the company's stock valued at $6,469,000 after purchasing an additional 21,240 shares during the last quarter. Finally, National Pension Service raised its position in Teva Pharmaceutical Industries by 4.9% in the second quarter. National Pension Service now owns 2,406,013 shares of the company's stock valued at $81,516,000 after purchasing an additional 112,357 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 2.5%

Shares of TEVA opened at $39.84 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $18.83 and a 52-week high of $40.79. The company has a quick ratio of 0.67, a current ratio of 0.88 and a debt-to-equity ratio of 1.56. The stock has a fifty day simple moving average of $36.51 and a two-hundred day simple moving average of $33.94. The company has a market capitalization of $46.43 billion, a PE ratio of 66.40, a price-to-earnings-growth ratio of 3.68 and a beta of 0.87.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.02 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 4.08% and a return on equity of 32.64%. The firm had revenue of $4.14 billion for the quarter. As a group, equities analysts forecast that Teva Pharmaceutical Industries will post 1.95 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company headquartered in Tel Aviv, Israel. Founded in 1901, the company develops, manufactures and distributes generic medicines, specialty pharmaceuticals, active pharmaceutical ingredients and biosimilars.

Teva's portfolio includes medicines for conditions affecting the central nervous system, respiratory system and other therapeutic areas. Its branded and specialty products include treatments such as Copaxone for multiple sclerosis, Austedo for movement disorders, Ajovy for migraine prevention and Uzedy for schizophrenia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.